Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NCNA NASDAQ:TRVN NASDAQ:VINC NASDAQ:VIRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNCNANuCana$3.19-0.3%$9.12$3.05▼$1,650.00$100K1.4574,036 shs155,055 shsTRVNTrevena$0.25+20,733.3%$0.68$0.00▼$7.85$240K0.412,161 shs6,905 shsVINCVincerx Pharma$0.03-24.9%$0.04$0.03▼$17.00$170K1.71556,253 shs145,819 shsVIRXViracta Therapeutics$0.01$0.01$0.01▼$0.56$389K1.061.11 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNCNANuCana-0.31%-7.27%-65.85%-54.56%-99.78%TRVNTrevena+20,733.33%-9.09%-72.53%-78.26%-94.08%VINCVincerx Pharma-24.94%-17.51%-11.92%-32.99%-99.79%VIRXViracta Therapeutics0.00%0.00%0.00%-46.56%-95.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNCNANuCana3.7461 of 5 stars3.54.00.00.03.82.51.3TRVNTrevena0.9225 of 5 stars3.02.00.00.00.00.00.6VINCVincerx Pharma2.4772 of 5 stars3.53.00.00.00.61.71.3VIRXViracta Therapeutics1.2345 of 5 stars3.30.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNCNANuCana 3.00Buy$5,000.00156,639.81% UpsideTRVNTrevena 2.00Hold$5.001,900.00% UpsideVINCVincerx Pharma 3.00Buy$40.00122,976.92% UpsideVIRXViracta Therapeutics 2.50Moderate Buy$1.1311,403.07% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNCNANuCanaN/AN/AN/AN/A$324.58 per shareN/ATRVNTrevena$443K0.54N/AN/A($11.07) per share-0.02VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/AVIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNCNANuCana-$24.28M-$646.16N/AN/AN/AN/A-592.28%-208.68%N/ATRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2025 (Estimated)VINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%9/4/2025 (Estimated)VIRXViracta Therapeutics-$51.06M-$1.10N/A∞N/AN/A-1,899.61%-114.21%11/11/2025 (Estimated)Latest NCNA, VIRX, VINC, and TRVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025NCNANuCana-$2.7456-$0.16+$2.5856-$0.16N/AN/A6/2/2025Q1 2025NCNANuCana-$2.5820-$126.00-$123.4180-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNCNANuCanaN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNCNANuCanaN/A1.581.58TRVNTrevenaN/A2.422.42VINCVincerx PharmaN/A2.172.17VIRXViracta TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNCNANuCana44.00%TRVNTrevena13.56%VINCVincerx Pharma44.02%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipNCNANuCana31.20%TRVNTrevena2.70%VINCVincerx Pharma15.60%VIRXViracta Therapeutics10.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNCNANuCana3030,00021,000Not OptionableTRVNTrevena40959,000841,000OptionableVINCVincerx Pharma605.23 million1.89 millionNot OptionableVIRXViracta Therapeutics2039.74 million35.50 millionNo DataNCNA, VIRX, VINC, and TRVN HeadlinesRecent News About These CompaniesCalif. biotech company once worth $476M lays off every remaining employeeFebruary 11, 2025 | msn.comViracta Therapeutics Terminates Employees & Winds Down OperationsFebruary 8, 2025 | contractpharma.comCViracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of OperationsFebruary 6, 2025 | finanznachrichten.deViracta Therapeutics Shuts Down Operations, Lays Off All StaffFebruary 6, 2025 | precisionmedicineonline.comPViracta Therapeutics terminates employees, to wind down operationsFebruary 6, 2025 | markets.businessinsider.comViracta Therapeutics to cease operations and seek alternativesFebruary 5, 2025 | msn.comViracta Therapeutics Winds Down Operations, Terminates EmployeesFebruary 5, 2025 | marketwatch.comViracta Therapeutics hits end of the line, laying off all workers and winding downFebruary 5, 2025 | fiercebiotech.comFViracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of OperationsFebruary 5, 2025 | quiverquant.comQViracta Therapeutics Announces Wind Down of OperationsFebruary 5, 2025 | globenewswire.comWhy Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?February 4, 2025 | bovnews.comBVIRX stock plunges to 52-week low, touches $0.08February 3, 2025 | msn.comViracta Therapeutics to be delisted from NasdaqFebruary 3, 2025 | msn.comViracta Therapeutics strikes deal to avoid defaultJanuary 25, 2025 | msn.comViracta Therapeutics Inc (VIRX) Stock Trading RecapJanuary 10, 2025 | bovnews.comBVIRX’s Unexpected Surge: What’s Next?January 6, 2025 | bovnews.comBViracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?January 3, 2025 | bovnews.comBCash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining optionsJanuary 3, 2025 | fiercebiotech.comFLeerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) StockDecember 30, 2024 | bovnews.comBServiceTitan initiated, Viracta downgraded: Wall Street's top analyst callsDecember 27, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCNA, VIRX, VINC, and TRVN Company DescriptionsNuCana NASDAQ:NCNA$3.19 -0.01 (-0.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.21 +0.02 (+0.63%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Trevena NASDAQ:TRVN$0.25 +0.25 (+20,733.33%) As of 08/29/2025 02:24 PM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Vincerx Pharma NASDAQ:VINC$0.03 -0.01 (-24.94%) As of 08/29/2025 03:26 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Viracta Therapeutics NASDAQ:VIRXViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
